Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis

• Main Authors: Hussien Ahmed (Author), Abdelrahman I. Abushouk (Author), Attia Attia (Author), Mohamed Gadelkarim (Author), Mohamed Gabr (Author), Ahmed Negida (Author), Mohamed M. Abdel-Daim (Author)
• Format: Book
• Published: Elsevier, 2018-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Velpatasvir is a newly FDA-approved inhibitor of hepatitis C virus (HCV) NS5A protein. We performed this systematic review and meta-analysis to investigate the safety and efficacy of velpatasvir plus sofosbuvir in the treatment of chronic HCV infection. A computerized literature search of PubMed, SC...